Drug Design and Discovery in Alzheimer's Disease -

Drug Design and Discovery in Alzheimer's Disease (eBook)

eBook Download: PDF | EPUB
2015 | 1. Auflage
784 Seiten
Elsevier Science (Verlag)
978-0-12-803960-1 (ISBN)
Systemvoraussetzungen
Systemvoraussetzungen
92,95 inkl. MwSt
  • Download sofort lieferbar
  • Zahlungsarten anzeigen
Drug Design and Discovery in Alzheimer's Disease includes expert reviews of recent developments in Alzheimer's disease (AD) and neurodegenerative disease research. Originally published by Bentham as Frontiers in Drug Design and Discovery, Volume 6and now distributed by Elsevier, this compilation of the sixteen articles, written by leading global researchers, focuses on key developments in the understanding of the disease at molecular levels, identification and validation of molecular targets, as well as innovative approaches towards drug discovery, development, and delivery. Beginning with an overview of AD pharmacotherapy and existing blockbuster drugs, the reviews cover the potential of both natural and synthetic small molecules; the role of cholinesterases in the on-set and progression of AD and their inhibition; the role of beta-site APP clearing enzyme-1 (BACE-1) in the production of á-amyloid proteins, one of the key reasons of the progression of AD; and other targets identified for AD drug discovery. - Edited and written by leading experts in Alzheimer's disease (AD) and other neurodegenerative disease drug development - Describes existing drugs for AD and current molecular understanding of the condition - Reviews recent advances in the field, including coverage of cholinesterases, BACE-1, and other drug development targets
Drug Design and Discovery in Alzheimer's Disease includes expert reviews of recent developments in Alzheimer's disease (AD) and neurodegenerative disease research. Originally published by Bentham as Frontiers in Drug Design and Discovery, Volume 6and now distributed by Elsevier, this compilation of the sixteen articles, written by leading global researchers, focuses on key developments in the understanding of the disease at molecular levels, identification and validation of molecular targets, as well as innovative approaches towards drug discovery, development, and delivery. Beginning with an overview of AD pharmacotherapy and existing blockbuster drugs, the reviews cover the potential of both natural and synthetic small molecules; the role of cholinesterases in the on-set and progression of AD and their inhibition; the role of beta-site APP clearing enzyme-1 (BACE-1) in the production of -amyloid proteins, one of the key reasons of the progression of AD; and other targets identified for AD drug discovery. - Edited and written by leading experts in Alzheimer's disease (AD) and other neurodegenerative disease drug development- Describes existing drugs for AD and current molecular understanding of the condition- Reviews recent advances in the field, including coverage of cholinesterases, BACE-1, and other drug development targets

List of Contributors


A. Michael Crider     United Arab Emirates University, Faculty of Medicine and Health Sciences, Department Pharmacology and Therapeutics, Al Ain, UAE

Abdu Adem     Department of Pharmacology and Therapeutics, Faculty of Medicine and Health Sciences, United Arab Emirates University, Al-Ain, UAE

Adel M. Abuzenadah     King Fahd Medical Research Center, King Abdulaziz University, P. O. Box 80216, Jeddah 21589, Saudi Arabia

Ali Jawad     Department of Applied Physics, Zakir Husain College of Engineering and Technology, Aligarh Muslim University, Aligarh UP, India

Benjamin P. Repsold     Pharmaceutical Chemistry, North-West University, Private Bag X6001, Potchefstroom, 2520, South Africa

Boris Decourt     Banner Sun Health Research Institute, Sun City, AZ, USA

Carmen Martínez-Rincón     Nursing Department, Complutense University of Madrid, Spain

Daniel Jun     University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic

Darrick Pope     Department of Chemistry and Biochemistry, Duquesne University, Pittsburgh, PA 15282, USA

David F. Fischer     BioFocus; Leiden, The Netherlands

David William Klaver     Alzheimer’s Disease Research Laboratory, Department of Neuroscience, Tufts University School of Medicine, Boston, MA, USA

Dolores Rodríguez-Martínez     Nursing Department, Complutense University of Madrid, Spain

Eric A. Owens     Department of Chemistry, Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, Georgia, 30303, USA

Eugenie Nepovimova     Department of Toxicology, Faculty of Military Health Sciences, Trebesska 1575, 500 01 Hradec Kralove, Czech Republic

Faizul H. Nasim     Department of Chemistry, BJ Campus, The Islamia University of Bahawalpur, Bahawalpur, Pakistan

Fares Zeidán-Chuliá     Center of Oxidative Stress Research, Department of Biochemistry, Postgraduate Program in Biological Sciences: Biochemistry, Institute of Basic Health Sciences, Federal University of Rio Grande do Sul, Porto Alegre, RS, Brazil

Farhan Jalees Ahmad     Nanomedicine Research Lab, Department of Pharmaceutics, Faculty of Pharmacy, Jamia Hamdard, New Delhi 110062, India

Farzana L. Ansari     Department of Chemistry, Quaid-i-Azam University, Islamabad 45320, Pakistan

Filip Zemek     Department of Toxicology, Faculty of Military Health Sciences, Trebesska 1575, 500 01 Hradec Kralove, Czech Republic

Giuseppina Tesco     Alzheimer’s Disease Research Laboratory, Department of Neuroscience, Tufts University School of Medicine, Boston, MA, USA

Gjumrakch Aliev     Department of Health Science and Healthcare Administration, University of Atlanta, Atlanta, GA, USA, and GALLY International Biomedical Research Consulting LLC, San Antonio, TX, USA

Iqbal Ahmad     Nanomedicine Research Lab, Department of Pharmaceutics, Faculty of Pharmacy, Jamia Hamdard, New Delhi 110062, India

Ismael Ortuño-Soriano     Institute for Health Research at the San Carlos Clinical Hospital (IdISSC), Madrid, Spain; Nursing Department, Complutense University of Madrid, Spain

Jacobus P. Petzer     Pharmaceutical Chemistry, North-West University, Private Bag X6001, Potchefstroom, 2520, South Africa

Jacques Joubert     School of Pharmacy, University of the Western Cape, Private Bag X17, Bellville 7535, South Africa

Jan Korabecny     Department of Toxicology, Faculty of Military Health Sciences, Trebesska 1575, 500 01 Hradec Kralove, Czech Republic

Javed Ahmad     Nanomedicine Research Lab, Department of Pharmaceutics, Faculty of Pharmacy, Jamia Hamdard, New Delhi 110062, India

José Cláudio Fonseca Moreira     Center of Oxidative Stress Research, Department of Biochemistry, Postgraduate Program in Biological Sciences: Biochemistry, Institute of Basic Health Sciences, Federal University of Rio Grande do Sul, Porto Alegre, RS, Brazil

José L. Pacheco-del-Cerro     Nursing Department, Complutense University of Madrid, Spain

Julie Frearson     BioFocus; Chesterford Research Park, Saffron Walden, Essex, CB10 1XL, UK

Kamil Kuca     University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic

Kamil Musilek     University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic

Karin E. Sandoval     Department of Pharmaceutical Sciences, Southern Illinois University Edwardsville, Edwardsville, Illinois 62026, USA

Katarina Spilovska     Department of Toxicology, Faculty of Military Health Sciences, Trebesska 1575, 500 01 Hradec Kralove, Czech Republic

Kenneth A. Witt     Department of Pharmaceutical Sciences, Southern Illinois University Edwardsville, Edwardsville, Illinois 62026, USA

Lara Pacheco-Cuevas     Nursing Department, Complutense University of Madrid, Spain

Louis H.A. Prins     Department of Pharmacy, University of Namibia, Windhoek, Namibia

Maged M. Henary     Department of Chemistry, Center for Diagnostics and Therapeutics, Center for Biotechnology and Drug Design, Georgia State University, Atlanta, Georgia, 30303, USA

Maria Kontoyianni     Department of Pharmaceutical Sciences, Southern Illinois University Edwardsville, Edwardsville, Illinois 62026, USA

Marwan Sabbagh     Banner Sun Health Research Institute, Sun City, AZ, USA

Mauricio Alcolea-Palafox     Chemical-Physics Department, Chemistry Faculty, Complutense University of Madrid, Spain

Michael Cascio     Department of Chemistry and Biochemistry, Duquesne University, Pittsburgh, PA 15282, USA

Michael D. Wall     BioFocus; Chesterford Research Park, Saffron Walden, Essex, CB10 1XL, UK

MiMi Macias     Banner Sun Health Research Institute, Sun City, AZ, USA

Mohamed A. Embaby     Department of Chemistry, Faculty of Sciences & Arts Khulais, King Abdulaziz University, Jeddah, KSA

Mohammad A. Kamal     King Fahd Medical Research Center, King Abdulaziz University, P. O. Box 80216, Jeddah 21589, Saudi Arabia

Mohammad Zaki Ahmad     Department of Pharmaceutics, College of Pharmacy, Najran University, Saudi Arabia

Nasimudeen R. Jabir     King Fahd Medical Research Center, King Abdulaziz University, P. O. Box 80216, Jeddah 21589, Saudi Arabia

Nigel H. Grieg     Drug Design & Development Section, Laboratory of Neurosciences, Intramural Research Program, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA

Nighat Sultana     Pharmaceutical Research Center, PCSIR Laboratories Complex, Shahrah-e-Dr. Salimuzzaman Siddiqui, Karachi 75280, Pakistan

Omar Aziz     BioFocus; Chesterford Research Park, Saffron Walden, Essex, CB10 1XL,...

PDFPDF (Adobe DRM)
Größe: 46,8 MB

Kopierschutz: Adobe-DRM
Adobe-DRM ist ein Kopierschutz, der das eBook vor Mißbrauch schützen soll. Dabei wird das eBook bereits beim Download auf Ihre persönliche Adobe-ID autorisiert. Lesen können Sie das eBook dann nur auf den Geräten, welche ebenfalls auf Ihre Adobe-ID registriert sind.
Details zum Adobe-DRM

Dateiformat: PDF (Portable Document Format)
Mit einem festen Seiten­layout eignet sich die PDF besonders für Fach­bücher mit Spalten, Tabellen und Abbild­ungen. Eine PDF kann auf fast allen Geräten ange­zeigt werden, ist aber für kleine Displays (Smart­phone, eReader) nur einge­schränkt geeignet.

Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen eine Adobe-ID und die Software Adobe Digital Editions (kostenlos). Von der Benutzung der OverDrive Media Console raten wir Ihnen ab. Erfahrungsgemäß treten hier gehäuft Probleme mit dem Adobe DRM auf.
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen eine Adobe-ID sowie eine kostenlose App.
Geräteliste und zusätzliche Hinweise

Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.

EPUBEPUB (Adobe DRM)
Größe: 16,2 MB

Kopierschutz: Adobe-DRM
Adobe-DRM ist ein Kopierschutz, der das eBook vor Mißbrauch schützen soll. Dabei wird das eBook bereits beim Download auf Ihre persönliche Adobe-ID autorisiert. Lesen können Sie das eBook dann nur auf den Geräten, welche ebenfalls auf Ihre Adobe-ID registriert sind.
Details zum Adobe-DRM

Dateiformat: EPUB (Electronic Publication)
EPUB ist ein offener Standard für eBooks und eignet sich besonders zur Darstellung von Belle­tristik und Sach­büchern. Der Fließ­text wird dynamisch an die Display- und Schrift­größe ange­passt. Auch für mobile Lese­geräte ist EPUB daher gut geeignet.

Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen eine Adobe-ID und die Software Adobe Digital Editions (kostenlos). Von der Benutzung der OverDrive Media Console raten wir Ihnen ab. Erfahrungsgemäß treten hier gehäuft Probleme mit dem Adobe DRM auf.
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen eine Adobe-ID sowie eine kostenlose App.
Geräteliste und zusätzliche Hinweise

Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.

Mehr entdecken
aus dem Bereich